Relacorilant (Lifyorli) plus nab-paclitaxel has posted final overall survival results in ROSELLA, a phase 3 study in platinum-resistant ovarian cancer, delivering a statistically significant survival benefit versus nab-paclitaxel alone. Presented at the 2026 SGO Annual Meeting, the regimen cut the risk of death by 35% (HR 0.65, 2-sided stratified log-rank P = .0004). In the relacorilant-combination arm (n = 188), median OS reached 16.0 months (95% CI 13.0-18.3) compared with 11.9 months (95% CI 10.0-13.8) with nab-paclitaxel monotherapy (n = 193). The separation favored the combination across prespecified subgroups, including prior PARP inhibitor exposure and platinum-free interval length. The report also highlights translation to clinical practice: the combination was FDA-approved in March 2026 and is now listed as a preferred option in NCCN guidelines for platinum-resistant ovarian cancer.